BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29642099)

  • 1. Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience.
    Ferry I; Kolesnikov-Gauthier H; Oudoux A; Cougnenc O; Schleiermacher G; Michon J; Bogart E; Chastagner P; Proust S; Valteau-Couanet D; Defachelles AS
    J Pediatr Hematol Oncol; 2018 Aug; 40(6):426-432. PubMed ID: 29642099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
    French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
    Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of
    Sevrin F; Kolesnikov-Gauthier H; Cougnenc O; Bogart E; Schleiermacher G; Courbon F; Gambart M; Giraudet AL; Corradini N; Badel JN; Rault E; Oudoux A; Deley MCL; Valteau-Couanet D; Defachelles AS
    Pediatr Blood Cancer; 2023 Nov; 70(11):e30615. PubMed ID: 37574821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients.
    Pasqualini C; Dufour C; Goma G; Raquin MA; Lapierre V; Valteau-Couanet D
    Bone Marrow Transplant; 2016 Feb; 51(2):227-31. PubMed ID: 26524264
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Giardino S; Piccardo A; Conte M; Puntoni M; Bertelli E; Sorrentino S; Montera M; Risso M; Caviglia I; Altrinetti V; Lanino E; Faraci M; Garaventa A
    Pediatr Blood Cancer; 2021 Feb; 68(2):e28775. PubMed ID: 33099289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tandem high-dose chemotherapy with autologous stem cell rescue for stage M high-risk neuroblastoma: Experience using melphalan/etoposide/carboplatin and busulfan/melphalan regimens.
    Kato S; Kubota Y; Watanabe K; Hogetsu K; Arakawa Y; Koh K; Takita J; Hiwatari M
    Pediatr Transplant; 2020 Nov; 24(7):e13772. PubMed ID: 32543778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database.
    Desai AV; Seif AE; Li Y; Getz K; Fisher BT; Huang V; Mante A; Aplenc R; Bagatell R
    Pediatr Blood Cancer; 2016 May; 63(5):901-7. PubMed ID: 26797923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan.
    Kraal KC; Tytgat GA; van Eck-Smit BL; Kam B; Caron HN; van Noesel M
    Pediatr Blood Cancer; 2015 Nov; 62(11):1886-91. PubMed ID: 25981988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility and Safety of Treosulfan, Melphalan, and Thiotepa-Based Megachemotherapy with Autologous or Allogeneic Stem Cell Transplantation in Heavily Pretreated Children with Relapsed or Refractory Neuroblastoma.
    Wawrzyniak-Dzierżek E; Gajek K; Rybka B; Ryczan-Krawczyk R; Węcławek-Tompol J; Raciborska A; Mielcarek-Siedziuk M; Frączkiewicz J; Salamonowicz M; Kałwak K; Rosa M; Ślęzak A; Ussowicz M
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1792-1797. PubMed ID: 31085306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
    Matthay KK; Tan JC; Villablanca JG; Yanik GA; Veatch J; Franc B; Twomey E; Horn B; Reynolds CP; Groshen S; Seeger RC; Maris JM
    J Clin Oncol; 2006 Jan; 24(3):500-6. PubMed ID: 16421427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database.
    Desai AV; Li Y; Getz K; Seif AE; Fisher B; Huang V; Aplenc R; Bagatell R
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27372. PubMed ID: 30070014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporation of high-dose
    Lee JW; Lee S; Cho HW; Ma Y; Yoo KH; Sung KW; Koo HH; Cho EJ; Lee SK; Lim DH
    J Hematol Oncol; 2017 May; 10(1):108. PubMed ID: 28511709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetry-based high-activity therapy with
    Genolla J; Rodriguez T; Minguez P; Lopez-Almaraz R; Llorens V; Echebarria A
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1567-1575. PubMed ID: 30838430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.
    Yanik GA; Villablanca JG; Maris JM; Weiss B; Groshen S; Marachelian A; Park JR; Tsao-Wei D; Hawkins R; Shulkin BL; Jackson H; Goodarzian F; Shimada H; Courtier J; Hutchinson R; Haas-Koga D; Hasenauer CB; Czarnecki S; Katzenstein HM; Matthay KK
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):673-81. PubMed ID: 25639769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and effectiveness of treatment strategy of tandem high-dose chemotherapy and autologous stem cell transplantation in combination with
    Suh JK; Koh KN; Min SY; Kim YS; Kim H; Im HJ; Namgoong JM; Kim DY; Ahn SD; Lee JJ; Seo JJ
    Pediatr Transplant; 2020 Mar; 24(2):e13658. PubMed ID: 31960542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy.
    Valteau-Couanet D; Le Deley MC; Bergeron C; Ducassou S; Michon J; Rubie H; Le Teuff G; Coze C; Plantaz D; Sirvent N; Bouzy J; Chastagner P; Hartmann O
    Pediatr Blood Cancer; 2014 Jun; 61(6):977-81. PubMed ID: 23970413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma.
    Yanik GA; Levine JE; Matthay KK; Sisson JC; Shulkin BL; Shapiro B; Hubers D; Spalding S; Braun T; Ferrara JL; Hutchinson RJ
    J Clin Oncol; 2002 Apr; 20(8):2142-9. PubMed ID: 11956276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.
    Weaver CH; Bensinger WI; Appelbaum FR; Lilleby K; Sandmaier B; Brunvand M; Rowley S; Petersdorf S; Rivkin S; Gooley T
    Bone Marrow Transplant; 1994 Nov; 14(5):813-9. PubMed ID: 7889015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
    Toporski J; Garkavij M; Tennvall J; Ora I; Gleisner KS; Dykes JH; Lenhoff S; Juliusson G; Scheding S; Turkiewicz D; Békássy AN
    Biol Blood Marrow Transplant; 2009 Sep; 15(9):1077-85. PubMed ID: 19660720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.
    Matthay KK; DeSantes K; Hasegawa B; Huberty J; Hattner RS; Ablin A; Reynolds CP; Seeger RC; Weinberg VK; Price D
    J Clin Oncol; 1998 Jan; 16(1):229-36. PubMed ID: 9440747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.